Daiichi Sankyo and its 15.000 employees in more than 20 countries are dedicated to the creation and supply of innovative pharmaceutical products. The group’s 2025 vision is to become a “Global Pharma Innovator with Competitive Advantage in Oncology”. Our research and development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology. Our European headquarters are in Munich, Germany and we have affiliates in 12 European countries. For more information: www.daiichi-sankyo.eu.